The UK government confirmed on October 6, 2026 that it will accept all 44 recommendations of the National Commission into the Regulation of AI in Healthcare and publish a delivery plan across the country. On the same day the Medicines and Healthcare products Regulatory Agency opened applications for Phase 3 of AI Airlock, its regulatory sandbox for AI-enabled medical devices. The combination of a lifecycle-based regulatory shift and a funded testing programme matters for vendors because market access rules and evidence requirements are being rewritten.
How the 44 recommendations will be delivered
The Commission report, published on September 10, 2026, called for moving away from one-time assessments toward proportionate regulation across the working life of AI-enabled medical devices. The government response commits MHRA to issue draft guidance by December 2026 on managing changes to such devices as they adapt and improve. Next year MHRA will start consulting on qualification and classification of AI-enabled devices, listed as the Commission first recommendation.
Further commitments include staged authorisation pathways that would allow promising AI tools to be used in the NHS earlier under close supervision while additional real-world evidence is collected. The response also adds work on patient engagement in decision-making, access to redress where care falls below expectations, and fair distribution of benefits across communities including underserved groups. A separate commitment covers keeping patients informed about when AI is used in their care.
The Commission was established by MHRA in September 2025 as an independent advisory body, chaired by Professor Alastair Denniston of the University of Birmingham with Deputy Chair Professor Henrietta Hughes, Patient Safety Commissioner for England. It drew on healthcare, technology, law, patient groups, government, the NHS and partners in England, Scotland, Wales and Northern Ireland, plus stakeholders from the United States, Europe and Singapore. Its evidence base included an open Call for Evidence, public deliberation events with The Health Foundation, work with seldom-heard groups supported by National Voices, and industry roundtables.
What AI Airlock Phase 3 changes for vendors
Phase 3 follows a pilot and Phase 2 programme and has three years of additional government funding, with the current phase funded until April 2029. Its focus is post-market surveillance and lifecycle regulation, testing with developers, regulators and healthcare partners how AI devices can be monitored after deployment. Evidence from the projects is intended to inform future MHRA guidance and policy. A webinar for applicants takes place on October 22, 2026 at 10:00, first innovators will be selected in November 2026, and candidates for the current wave should apply before October 31, 2026, with another shortlisting in Spring 2027.
Three priority topics define the phase: ongoing assurance across the lifecycle, including local infrastructure, workflow integration, data quality and user interaction; surveillance for settings with varying oversight such as remote, direct-to-consumer or higher-autonomy systems; and communication of performance, safety, update and rollback information to regulators, providers, professionals and patients. Proposals outside these topics may be filed as expressions of interest, but aligned applications receive priority. Each testing plan is bespoke, generally six to 12 months, across simulation workshops, a virtual digital testing space with real or synthetic data, and real-world observation outside patient pathways such as shadow deployment.
Eligibility requires potential patient benefit, an innovative product or concept, a regulatory challenge to address, and readiness for trial, with organisations of all sizes allowed and partnerships permitted. There is no fee for application or participation, but participants fund their own studies and testing, while the Information Commissioner Office supports the programme through data protection by design advice. Survey data cited in the report underlines the pressure: 77% of healthcare professional respondents called for complete overhaul or significant reform, two-thirds of industry respondents and half of providers viewed the framework as restricting innovation, and 65% disagreed that post-market surveillance is sufficient.
A full implementation roadmap with timelines and responsibilities across all 44 recommendations will follow by Spring 2027, overseen by a newly established Programme Board with regular progress updates. For business, that document plus the December 2026 draft guidance on change management will show how strict lifecycle monitoring, staged authorisation and disclosure duties translate into development cost and launch timing. Vendors active in the UK should track which evidence standards from AI Airlock become formal MHRA policy.
